Published in CMAJ on July 07, 2009
Use of fibrates in the United States and Canada. JAMA (2011) 2.82
The potential economic impact of restricted access to angiotensin-receptor blockers. CMAJ (2011) 2.22
Money left on the table: generic drug prices in Canada. Healthc Policy (2013) 1.92
From pharmaco-therapy to pharmaco-prevention: trends in prescribing to older adults in Ontario, Canada, 1997-2006. BMC Fam Pract (2010) 1.19
Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control study. Clin J Am Soc Nephrol (2010) 1.04
Potential savings of harmonising hospital and community formularies for chronic disease medications initiated in hospital. PLoS One (2012) 0.80
Rational use of medications: if Canada can't do it ... CMAJ (2009) 0.80
Epidemiology of cardioprotective pharmacological agent use in stable coronary heart disease. Indian Heart J (2013) 0.78
Costs of cardiovascular disease. CMAJ (2009) 0.75
Is immunity a mechanism contributing to statin-induced diabetes? Adipocyte (2015) 0.75
Pharmaceutical innovation: impact on expenditure and outcomes and subsequent challenges for pharmaceutical policy, with a special reference to Greece. Hippokratia (2014) 0.75
Trends in statin therapy initiation during the period 2000-2010 in Israel. Eur J Clin Pharmacol (2014) 0.75
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med (2001) 9.75
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA (2001) 9.16
Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol (2006) 4.02
Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol (2006) 3.20
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol (2006) 2.57
Drug spending in Canada: recent trends and causes. Med Care (2004) 2.45
The impact of the Canadian Hypertension Education Program on antihypertensive prescribing trends. Hypertension (2005) 2.15
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Can J Cardiol (2005) 2.03
Risk factors for cardiovascular disease in Canada. Can J Cardiol (2003) 1.64
Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001. Can J Cardiol (2003) 1.56
Class effects of statins in elderly patients with congestive heart failure: a population-based analysis. Am Heart J (2007) 1.53
Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ (2008) 1.51
"Breakthrough" drugs and growth in expenditure on prescription drugs in Canada. BMJ (2005) 1.24
Canadian prescription drug costs surpass 18 billion dollars. CMAJ (2005) 1.14
Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med (2006) 10.58
Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet (2006) 6.64
Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA (2003) 6.39
Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA (2002) 6.30
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ (2009) 6.21
The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol (2010) 5.54
Congenital heart disease in the general population: changing prevalence and age distribution. Circulation (2007) 5.16
A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J (2002) 4.65
Relative fitness and frailty of elderly men and women in developed countries and their relationship with mortality. J Am Geriatr Soc (2005) 4.48
Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care (2005) 4.30
Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation (2014) 3.78
Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ (2008) 3.63
Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation (2009) 3.55
Assessing the association of appropriateness of coronary revascularization and clinical outcomes for patients with stable coronary artery disease. J Am Coll Cardiol (2012) 3.45
Percutaneous transarterial aortic valve replacement in selected high-risk patients with aortic stenosis. Circulation (2007) 3.44
Effect of socioeconomic status on treatment and mortality after stroke. Stroke (2002) 3.44
Cancer risk related to low-dose ionizing radiation from cardiac imaging in patients after acute myocardial infarction. CMAJ (2011) 3.15
Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke (2008) 3.14
Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med (2002) 3.09
Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. J Am Coll Cardiol (2010) 3.07
Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA (2005) 3.05
Socioeconomic status and mortality after acute myocardial infarction. Ann Intern Med (2006) 3.02
Rhythm versus rate control therapy and subsequent stroke or transient ischemic attack in patients with atrial fibrillation. Circulation (2012) 2.96
National trends in rates of death and hospital admissions related to acute myocardial infarction, heart failure and stroke, 1994-2004. CMAJ (2009) 2.89
Comparing hierarchical modeling with traditional logistic regression analysis among patients hospitalized with acute myocardial infarction: should we be analyzing cardiovascular outcomes data differently? Am Heart J (2003) 2.88
Deriving ethnic-specific BMI cutoff points for assessing diabetes risk. Diabetes Care (2011) 2.87
Impact of hospital nursing care on 30-day mortality for acute medical patients. J Adv Nurs (2007) 2.85
Use of fibrates in the United States and Canada. JAMA (2011) 2.82
Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation (2008) 2.76
Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery: a review of randomized controlled trials. J Am Coll Cardiol (2005) 2.75
Automated variable selection methods for logistic regression produced unstable models for predicting acute myocardial infarction mortality. J Clin Epidemiol (2004) 2.69
Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA (2010) 2.61
Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared with other specialists. Circulation (2003) 2.61
Administrative Data Feedback for Effective Cardiac Treatment: AFFECT, a cluster randomized trial. JAMA (2005) 2.54
Prevalence of severe congenital heart disease after folic acid fortification of grain products: time trend analysis in Quebec, Canada. BMJ (2009) 2.50
Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med (2002) 2.45
Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation (2009) 2.40
Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ (2011) 2.34
Effects of contemporary troponin assay sensitivity on the utility of the early markers myoglobin and CKMB isoforms in evaluating patients with possible acute myocardial infarction. Clin Chim Acta (2007) 2.31
The use of the propensity score for estimating treatment effects: administrative versus clinical data. Stat Med (2005) 2.31
Improved outcomes with early collaborative care of ambulatory heart failure patients discharged from the emergency department. Circulation (2010) 2.29
IScore: a risk score to predict death early after hospitalization for an acute ischemic stroke. Circulation (2011) 2.29
Sex differences in carotid endarterectomy outcomes: results from the Ontario Carotid Endarterectomy Registry. Stroke (2003) 2.28
Adjunctive thrombectomy for acute myocardial infarction: A bayesian meta-analysis. Circ Cardiovasc Interv (2010) 2.27
Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures. CMAJ (2008) 2.23
Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada. Hypertension (2008) 2.23
The potential economic impact of restricted access to angiotensin-receptor blockers. CMAJ (2011) 2.22
Preoperative anxiety as a predictor of mortality and major morbidity in patients aged >70 years undergoing cardiac surgery. Am J Cardiol (2013) 2.18
Effectiveness of recanalization of chronic total occlusions: a systematic review and meta-analysis. Am Heart J (2010) 2.18
Trends in risk factors for cardiovascular disease in Canada: temporal, socio-demographic and geographic factors. CMAJ (2009) 2.16
Effect of cardiac and noncardiac conditions on survival after defibrillator implantation. J Am Coll Cardiol (2007) 2.15
Outcomes after aortic and mitral valve replacement surgery in Canada: 1994/95 to 1999/2000. Can J Cardiol (2004) 2.11
Children and adults with congenital heart disease lost to follow-up: who and when? Circulation (2009) 2.10
Evaluation of care and surveillance of cardiovascular disease: can we trust medico-administrative hospital data? Can J Cardiol (2012) 2.10
Statins and cancer risk. Am J Med (2008) 2.09
Bundle branch block patterns and long-term outcomes in heart failure. Int J Cardiol (2010) 2.07
Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication. Virology (2009) 2.07
Alternative smoking cessation aids: a meta-analysis of randomized controlled trials. Am J Med (2012) 2.06
Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. Circulation (2006) 2.05
Cardiovascular complications and mortality after diabetes diagnosis for South Asian and Chinese patients: a population-based cohort study. Diabetes Care (2013) 2.04
Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol (2005) 2.03
Prevalence and extent of obstructive coronary artery disease among patients undergoing elective coronary catheterization in New York State and Ontario. JAMA (2013) 2.03
Use of niacin in the United States and Canada. JAMA Intern Med (2013) 2.02
The effect of universal influenza immunization on mortality and health care use. PLoS Med (2008) 2.01
Transcatheter aortic valve implantation: impact on clinical and valve-related outcomes. Circulation (2009) 2.00
Changing mortality in congenital heart disease. J Am Coll Cardiol (2010) 1.99
Prevention and management of transcatheter balloon-expandable aortic valve malposition. Catheter Cardiovasc Interv (2008) 1.98
Traditional risk factors and a Genetic Risk Score are associated with age of first acute coronary syndrome. Heart (2014) 1.95
A percutaneous treatment algorithm for crossing coronary chronic total occlusions. JACC Cardiovasc Interv (2012) 1.95
The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ (2003) 1.94
Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Arch Intern Med (2012) 1.94
Atrial arrhythmias in adults with congenital heart disease. Circulation (2009) 1.94
Life expectancy after an index hospitalization for patients with heart failure: a population-based study. Am Heart J (2008) 1.92
Lifetime analysis of hospitalizations and survival of patients newly admitted with heart failure. Circ Heart Fail (2012) 1.92
Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med (2005) 1.91
Meta-analysis of ten trials on the effectiveness of the radial versus the femoral approach in primary percutaneous coronary intervention. Am J Cardiol (2011) 1.91
Large increases in hypertension diagnosis and treatment in Canada after a healthcare professional education program. Hypertension (2006) 1.89
Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial. J Am Coll Cardiol (2013) 1.86
Comparison of cardiovascular risk profiles among ethnic groups using population health surveys between 1996 and 2007. CMAJ (2010) 1.85
Use of ezetimibe in the United States and Canada. N Engl J Med (2008) 1.85
The nested case-control study in cardiology. Am Heart J (2003) 1.84
Early deaths in patients with heart failure discharged from the emergency department: a population-based analysis. Circ Heart Fail (2010) 1.83